Testosterone concentrations in diabetic and nondiabetic obese men

Sandeep Dhindsa, Michael G Miller, Cecilia L McWhirter, Donald E Mager, Husam Ghanim, Ajay Chaudhuri, Paresh Dandona, Sandeep Dhindsa, Michael G Miller, Cecilia L McWhirter, Donald E Mager, Husam Ghanim, Ajay Chaudhuri, Paresh Dandona

Abstract

Objective: To determine the prevalence of subnormal testosterone concentrations in patients with obesity and with type 2 diabetes in a primary care clinic population.

Research design and methods: Free testosterone concentrations of 1,849 men (1,451 nondiabetic and 398 diabetic) in the Hypogonadism In Males (HIM) study were analyzed. The HIM study was a U.S.-based cross-sectional study designed to define the prevalence of hypogonadism in men aged >45 years. Free testosterone was measured by equilibrium dialysis.

Results: The prevalence of subnormal free testosterone concentrations in lean, overweight, and obese nondiabetic men was 26% (n = 275), 29% (n = 687), and 40% (n = 489), respectively (P < 0.001 for trend), and 44% (n = 36), 44% (n = 135), and 50% (n = 227), respectively, in diabetic men (P = 0.46 for trend within group and P < 0.05 compared with nondiabetic men). The mean free testosterone concentration of diabetic men was significantly lower than that of nondiabetic men. Free testosterone concentrations were negatively and significantly (P < 0.001) related to age (r = -0.37), BMI (r = -0.18), and sex hormone-binding globulin (r = -0.11) in multiple regression analysis. The average decline of free testosterone concentrations was 7.8 pg/ml per decade in nondiabetic men and 8.4 pg/ml per decade in diabetic men.

Conclusions: Forty percent of obese nondiabetic men and 50% of obese diabetic men aged >or=45 years have subnormal free testosterone concentrations. In view of its high prevalence, obesity is probably the condition most frequently associated with subnormal free testosterone concentrations in males. The concomitant presence of diabetes is associated with an additional increase in the prevalence of subnormal free testosterone concentrations.

Figures

Figure 1
Figure 1
The prevalence of subnormal free testosterone (FT) concentrations in diabetic (DM, ) and nondiabetic (non-DM, ■) men separated into quartiles of age. Quartile 1 (aged 45–52 years) had 408 nondiabetic and 55 diabetic men. Quartile 2 (aged 53–59 years) had 378 nondiabetic and 82 diabetic men. Quartile 3 (aged 60–68 years) had 326 nondiabetic and 136 diabetic men. Quartile 4 (aged 69–91 years) had 339 nondiabetic and 125 diabetic men. The prevalence of subnormal free testosterone concentrations was calculated in each quartile for nondiabetic and diabetic men. The prevalence was then adjusted to the mean BMI (29.7 kg/m2) of the whole study population. A χ2 test was used to compare the prevalence among groups. A similar percentage of nondiabetic and diabetic men in quartile 1 had subnormal free testosterone (18 vs. 18%, P = 0.97). Nondiabetic men had a lower prevalence of subnormal free testosterone than diabetic men in the other three quartiles (quartile 2, 22 vs. 41%, P < 0.01; quartile 3, 32 vs. 50%, P < 0.01; and quartile 4, 58 vs. 67%, P = 0.05).
Figure 2
Figure 2
A: Inverse relationship of age with free testosterone concentration in nondiabetic (non-DM, ■) lean (r = −0.53, P < 0.001), overweight (r = −0.43, P < 0.001), and obese (r = −0.28, P < 0.001) men. Thus, although age could explain ∼25% of variability (R2) in free testosterone concentrations in nonobese individuals, it accounted for a significantly lower variability (8%) in free testosterone in obese nondiabetic men (P = 0.008). DM, , diabetic men. B: Inverse relationship of age with free testosterone in lean (, r = −0.57, P < 0.001), overweight (○, r = −0.49, P < 0.001), and obese (▽, r = −0.30, P < 0.001) diabetic men. Thus, although age could explain 25–30% of variability (R2) in free testosterone concentrations in nonobese individuals, it accounted for a significantly lower variability (9%) in free testosterone in obese diabetic men (P = 0.05 compared with nonobese men). C: Relationship of free testosterone with BMI in lean (, r = 0.01, P = 0.9), overweight (○, r = −0.08, P = 0.04), and obese (▽, r = −0.10, P = 0.03) non-diabetic men. D: Relationship of free testosterone with BMI in lean (, r = 0.13, P = 0.5), overweight (○, r = 0.03, P = 0.8), and obese (▽, r = −0.17, P < 0.01) diabetic men.
Figure 2
Figure 2
A: Inverse relationship of age with free testosterone concentration in nondiabetic (non-DM, ■) lean (r = −0.53, P < 0.001), overweight (r = −0.43, P < 0.001), and obese (r = −0.28, P < 0.001) men. Thus, although age could explain ∼25% of variability (R2) in free testosterone concentrations in nonobese individuals, it accounted for a significantly lower variability (8%) in free testosterone in obese nondiabetic men (P = 0.008). DM, , diabetic men. B: Inverse relationship of age with free testosterone in lean (, r = −0.57, P < 0.001), overweight (○, r = −0.49, P < 0.001), and obese (▽, r = −0.30, P < 0.001) diabetic men. Thus, although age could explain 25–30% of variability (R2) in free testosterone concentrations in nonobese individuals, it accounted for a significantly lower variability (9%) in free testosterone in obese diabetic men (P = 0.05 compared with nonobese men). C: Relationship of free testosterone with BMI in lean (, r = 0.01, P = 0.9), overweight (○, r = −0.08, P = 0.04), and obese (▽, r = −0.10, P = 0.03) non-diabetic men. D: Relationship of free testosterone with BMI in lean (, r = 0.13, P = 0.5), overweight (○, r = 0.03, P = 0.8), and obese (▽, r = −0.17, P < 0.01) diabetic men.

References

    1. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P: Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004;89:5462–5468
    1. Dhindsa S, Bhatia V, Dhindsa G, Chaudhuri A, Gollapudi GM, Dandona P: The effects of hypogonadism on body composition and bone mineral density in type 2 diabetic patients. Diabetes Care 2007;30:1860–1861
    1. Kapoor D, Aldred H, Clark S, Channer KS, Jones TH: Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007;30:911–917
    1. Grossmann M, Thomas MC, Panagiotopoulos S, Sharpe K, Macisaac RJ, Clarke S, Zajac JD, Jerums G: Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab 2008;93:1834–1840
    1. Tomar R, Dhindsa S, Chaudhuri A, Mohanty P, Garg R, Dandona P: Contrasting testosterone concentrations in type 1 and type 2 diabetes. Diabetes Care 2006;29:1120–1122
    1. Glass AR, Swerdloff RS, Bray GA, Dahms WT, Atkinson RL: Low serum testosterone and sex-hormone-binding-globulin in massively obese men. J Clin Endocrinol Metab 1977;45:1211–1219
    1. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C: Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006;60:762–769
    1. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM: Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006;91:1995–2010
    1. Vermeulen A, Verdonck L, Kaufman JM: A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666–3672
    1. Vermeulen A, Kaufman JM, Deslypere JP, Thomas G: Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. J Clin Endocrinol Metab 1993;76:1140–1146
    1. Zumoff B, Strain GW, Miller LK, Rosner W, Senie R, Seres DS, Rosenfeld RS: Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab 1990;71:929–931
    1. Giagulli VA, Kaufman JM, Vermeulen A: Pathogenesis of the decreased androgen levels in obese men. J Clin Endocrinol Metab 1994;79:997–1000
    1. Hofstra J, Loves S, van Wageningen B, Ruinemans-Koerts J, Jansen I, de Boer H: High prevalence of hypogonadotropic hypogonadism in men referred for obesity treatment. Neth J Med 2008;66:103–109
    1. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM: Prevalence of overweight and obesity in the United States, 1999–2004. JAMA 2006;295:1549–1555
    1. Selvin E, Feinleib M, Zhang L, Rohrmann S, Rifai N, Nelson WG, Dobs A, Basaria S, Golden SH, Platz EA: Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007;30:234–238
    1. Brüning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, Klein R, Krone W, Müller-Wieland D, Kahn CR: Role of brain insulin receptor in control of body weight and reproduction. Science 2000;289:2122–2125
    1. Jensen TK, Andersson AM, Jørgensen N, Andersen AG, Carlsen E, Petersen JH, Skakkebaek NE: Body mass index in relation to semen quality and reproductive hormones among 1,558 Danish men. Fertil Steril 2004;82:863–870
    1. Dandona P, Aljada A, Bandyopadhyay A: Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004;25:4–7
    1. Chandel A, Dhindsa S, Topiwala S, Chaudhuri A, Dandona P: Testosterone concentration in young patients with diabetes. Diabetes Care 2008;31:2013–2017
    1. Ding EL, Song Y, Manson JE, Hunter DJ, Lee CC, Rifai N, Buring JE, Gaziano JM, Liu S: Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med 2009;361:1152–1163
    1. Kapoor D, Clarke S, Channer KS, Jones TH: Erectile dysfunction is associated with low bioactive testosterone levels and visceral adiposity in men with type 2 diabetes. Int J Androl 2007;30:500–507
    1. Nielsen TL, Hagen C, Wraae K, Brixen K, Petersen PH, Haug E, Larsen R, Andersen M: Visceral and subcutaneous adipose tissue assessed by magnetic resonance imaging in relation to circulating androgens, sex hormone-binding globulin, and luteinizing hormone in young men. J Clin Endocrinol Metab 2007;92:2696–2705
    1. Caronia L, Dwyer A, Hayden D, Pitteloud N, Hayes F: Abrupt decrease in testosterone following an oral glucose load in men. Abstract presented at ENDO 09, 10–13 June 2009, Washington, DC, OR42-2

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj